Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Qiagen ( (QGEN) ).
Qiagen N.V. has announced a notification from the Netherlands Authority for the Financial Markets (AFM) regarding a change in voting rights involving BlackRock, Inc. This disclosure highlights BlackRock’s significant indirect holdings in Qiagen, which impacts the company’s capital interest and voting rights. The notification is part of regulatory compliance and reflects BlackRock’s substantial influence in Qiagen’s shareholder structure.
The most recent analyst rating on (QGEN) stock is a Hold with a $42.50 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products and services that enable customers to gain valuable insights from biological samples.
Average Trading Volume: 1,406,775
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.85B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue